➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Express Scripts
Boehringer Ingelheim
Merck

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,492,449


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,492,449 protect, and when does it expire?

Patent 9,492,449 protects ZYDELIG and is included in one NDA.

This patent has thirty-one patent family members in twelve countries.

Summary for Patent: 9,492,449
Title:Therapies for hematologic malignancies
Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, ##STR00001## wherein R is H, halo, or C1-C6 alkyl; R' is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
Inventor(s): Gallatin; W. Michael (Mercer Island, WA), Ulrich; Roger G. (Foster City, CA), Giese; Neill A. (San Francisco, CA), Lannutti; Brian (Seattle, WA), Miller; Langdon (Lebanon, NJ), Jahn; Thomas M. (Seattle, WA)
Assignee: Gilead Calistoga LLC (Foster City, CA)
Application Number:13/417,185
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,492,449

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ⤷  Free Forever Trial
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,492,449

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009313878 ⤷  Free Forever Trial
Australia 2016201634 ⤷  Free Forever Trial
Australia 2017200837 ⤷  Free Forever Trial
Australia 2018204264 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Moodys
Express Scripts
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.